BakaleRP, WaldSA, ButlerHT, GaoY, HongY, NieX, et al. Albuterol. A pharmaceutical chemistry review of R-, S-, and RS-albuterol. Clin Rev Allergy Immunol. 1996;14:7–35.
2.
TempletonA.G.B., ChapmanI.D., ChilversE.R., MorleyJ., HandleyD.A.Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther. 1998;11:1–6.
3.
MitraS, UgurM, UgurO, GoodmanH.M., McCulloughJ.R., YamaguchiH.(S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phosphoplipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol. 1998;53:347–354.
4.
VolcheckGW, GleichGJ, KitaH.Pro- and anti-inflammatory effects of beta adrenergic agonists on eosinophil response to IL-5. J Allergy Clin Immunol. 1998;101:S35.
5.
JohanssonFJ, RydbergI, AbergG, AnderssonRGG. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol. 1996;14:57–64.
6.
LipworthBJ, ClarkDJ, KochP, ArbeenyC.Pharmacokinetics and extrapulmonary beta-2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax. 1997;52:849–852.
BoultonDW, FawcettJP. Pharmcokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Clin Pharmacol Ther. 1997;62:138–144.
9.
SchmekelB, RydbergI, NorlanderB, SjöswärdKN, AhlnerJ, AnderssonRGG. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J. 1999;13:1230–1235.
10.
DhandR, GoodeM, ReidR, FinkJB, FaheyPJ, TobinMJ. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med. 1999;160:1136–1141.
11.
CockroftDW, McParlandCP, BrittoSA, SwystunVA, RutherfordBC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet. 1993;342:833–837.
12.
O'ConnorBJ, AikmanSL, BarnesPJ. Tolerance to the nonbronchodilator effects of inhaled beta2-agonists in asthma. N Engl J Med. 1992;327:1204–1208.
13.
Perrin-FayolleM.Salbutamol in the treatment of asthma. Lancet. 1995;346:1101.
14.
CockcroftDW, SwystunVA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax. 1997;52:845–848.
15.
CockcroftDW, DavisBE, SwystunVA, MarciniukDD. Tolerance to the bronchoprotective effect of B₂ agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol. 1999;103:1049–1053.
16.
NelsonHS, BenschG, PleskowWW, DiSantostefanoR, DeGrawS, ReasnerDS, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998;102:943–952.
17.
GawchikSM, SaccarCL, NoonanM, ReasnerDS, DeGrawSS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol. 1999;103:615–621.
